<DOC>
	<DOCNO>NCT00025272</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine topotecan , carboplatin , etoposide treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity profile maximum tolerate dose sequential topotecan , carboplatin , etoposide patient chemotherapy-naive extensive stage small cell lung cancer . ( Phase I close accrual 04/04/2003 ) . - Determine response rate duration response patient treat regimen . - Determine failure-free overall survival patient treat regimen . - Determine pharmacokinetics pharmacodynamics topotecan etoposide schedule patient . OUTLINE : This dose-escalation , multicenter study topotecan etoposide . ( Phase I close accrual 04/04/2003 ) . Patients receive oral topotecan day 1-5 , carboplatin IV 30 minute day 6 , oral etoposide day 6-10 . Treatment continue every 3 week 2 course absence disease progression unacceptable toxicity . Patients complete response ( CR ) partial response second course receive 4 additional course . Patients brain metastases initial presentation undergo whole-brain irradiation chemotherapy regimen . Patients without brain metastasis initial presentation achieve CR undergo prophylactic whole-brain irradiation . Sequential dose escalation topotecan follow sequential dose escalation etoposide . Cohorts 3-6 patient receive escalate dos topotecan etoposide maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . ( Phase I close accrual 04/04/2003 ) . In phase II part study , additional 11-40 patient accrue receive topotecan , carboplatin , etoposide MTD . Patients follow every 3 month . PROJECTED ACCRUAL : A maximum 50 patient ( 3-10 phase I 11-40 phase II ) accrue study . ( Phase I close accrual 04/04/2003 )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm extensive stage small cell lung cancer Measurable evaluable disease Pleural effusion allow , consider measurable evaluable disease Brain metastases allow provide neurologically stable study entry PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 2 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow capsule No concurrent prior malignancy within past 5 year except inactive nonmelanomatous skin cancer carcinoma situ cervix No serious medical psychiatric illness would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy brain metastasis allow No prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>